Following a reallocation of resources completed in July, the company has extended its cash runway into the fourth quarter of 2025. This strategic financial management ensures that sufficient resources are available to continue delivering on meaningful clinical data from ongoing research and development efforts. The company remains steadfast in its commitment to prudent resource allocation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PASG:
- Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
- Passage Bio, Inc. (PASG) Q3 Earnings Cheat Sheet
- Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference
- Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference
